Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Phase III study of NS-304 in intermittent claudication due to arteriosclerosis obliterans
jRCT2071250135Phase 3Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in intermittent claudication (IC) and arteriosclerosis obliterans, sponsored by Nippon Shinyaku. Primary endpoint: Safety of Long-Term Administration (52 weeks) of NS-304. Started Mar 2026; status: recruiting.
02
Drugs
selexipag
03
Conditions
intermittent claudication (IC)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2071250135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250135.